UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.540

Sortiert nach

Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease

Biochemical pharmacology, 2020-08, Vol.178, p.114103, Article 114103

2020

Link zum Volltext

Verfügbarkeit prüfen

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket

Cell chemical biology, 2016-11, Vol.23 (11), p.1335-1340

2016

Link zum Volltext

Verfügbarkeit prüfen

Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol

The Journal of biological chemistry, 2015-02, Vol.290 (8), p.4573-4589

2015

Link zum Volltext

Verfügbarkeit prüfen

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)

The Journal of immunology (1950), 2011-04, Vol.186 (7), p.4234-4243

2011

Link zum Volltext

Verfügbarkeit prüfen

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases

PloS one, 2016-10, Vol.11 (10), p.e0164080-e0164080

2016

Link zum Volltext

Verfügbarkeit prüfen

Covalent docking of large libraries for the discovery of chemical probes

Nature chemical biology, 2014-12, Vol.10 (12), p.1066

2014

Link zum Volltext

Verfügbarkeit prüfen

The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis

Neoplasia (New York, N.Y.), 2013-07, Vol.15 (7), p.848-IN45

2013

Link zum Volltext

Verfügbarkeit prüfen

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

Blood, 2014-11, Vol.124 (20), p.3092-3100

2014

Link zum Volltext

Verfügbarkeit prüfen

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

Journal of Immunology Research, 2014-01, Vol.2014, p.283617-7

2014

Link zum Volltext

Verfügbarkeit prüfen

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities

The Journal of biological chemistry, 2015-11, Vol.290 (48), p.29022-29034

2015

Link zum Volltext

Verfügbarkeit prüfen

Janus Kinase 3 is Expressed in Erythrocytes, Phosphorylated Upon Energy Depletion and Involved in the Regulation of Suicidal Erythrocyte Death

Cellular physiology and biochemistry, 2011-01, Vol.27 (5), p.547-556

2011

Link zum Volltext

Verfügbarkeit prüfen

JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis

Journal of the American Society of Nephrology, 2015-12, Vol.26 (12), p.3060-3071

2015

Link zum Volltext

Verfügbarkeit prüfen

Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma

Cancer discovery, 2012-07, Vol.2 (7), p.591-597

2012

Link zum Volltext

Verfügbarkeit prüfen

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma

Leukemia, 2014-02, Vol.28 (2), p.338-348

2014

Link zum Volltext

Verfügbarkeit prüfen

Novel JAK3 -Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type

The American journal of pathology, 2017-05, Vol.187 (5), p.980-986

2017

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor

The Journal of pharmacology and experimental therapeutics, 2017-05, Vol.361 (2), p.229

2017

Link zum Volltext

Verfügbarkeit prüfen

In vivo impact of JAK3 A573V mutation revealed using zebrafish

Cellular and molecular life sciences : CMLS, 2022-06, Vol.79 (6), p.322-322, Article 322

2022

Link zum Volltext

Verfügbarkeit prüfen

JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma

International immunopharmacology, 2020-09, Vol.86, p.106706-106706, Article 106706

2020

Link zum Volltext

Verfügbarkeit prüfen

In silico screening of a series of 1,6-disubstituted 1 H -pyrazolo[3,4- d ]pyrimidines as potential selective inhibitors of the Janus kinase 3

Journal of biomolecular structure & dynamics, 2024-06, Vol.42 (9), p.4456-4474

2024

Link zum Volltext

Verfügbarkeit prüfen

In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives

Journal of biomolecular structure & dynamics, 2024-06, Vol.42 (9), p.4817-4833

2024

Link zum Volltext

Verfügbarkeit prüfen

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

Leukemia, 2007-08, Vol.21 (8), p.1658-1668

2007

Link zum Volltext

Verfügbarkeit prüfen

JAK3: A two-faced player in hematological disorders

The international journal of biochemistry & cell biology, 2009-12, Vol.41 (12), p.2376-2379

2009

Link zum Volltext

Verfügbarkeit prüfen

Janus kinase 3 deficiency caused by a homozygous synonymous exonic mutation that creates a dominant splice site

Journal of allergy and clinical immunology, 2017-07, Vol.140 (1), p.268-271.e6

2017

Link zum Volltext

Verfügbarkeit prüfen

Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting

Bioorganic & medicinal chemistry letters, 2017-09, Vol.27 (18), p.4229-4237

2017

Link zum Volltext

Verfügbarkeit prüfen

Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity

The Journal of biological chemistry, 2019-11, Vol.294 (48), p.18337-18348

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.540

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.371)
Mit Volltextzugriff
(2.338)

Publikationsform

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.239)
Life Sciences & Biomedicine
(2.105)
Humans
(1.688)
Animals
(1.280)
Signal Transduction
(859)
Mice
(788)
Phosphorylation
(639)
Janus Kinase 3
(629)
Male
(536)
Janus Kinase 2
(529)
Biochemistry & Molecular Biology
(487)
Protein-Tyrosine Kinases - Metabolism
(475)
Female
(463)
Cell Biology
(444)
Kinases
(442)
Stat3 Transcription Factor - Metabolism
(422)
Immunology
(407)
Signal Transduction - Drug Effects
(400)
Biological And Medical Sciences
(392)
Janus Kinase
(378)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Journal Of Biological Chemistry
(113)
The Journal Of Immunology
(86)
Blood
(83)
Plos One
(63)
Oncogene
(44)
Leukemia
(39)
Molecular Medicine Reports
(34)
Febs Letters
(32)
Journal Of Biological Chemistry
(30)
Proceedings Of The National Academy Of Sciences - Pnas
(30)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket

Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases

Covalent docking of large libraries for the discovery of chemical probes

The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities

Janus Kinase 3 is Expressed in Erythrocytes, Phosphorylated Upon Energy Depletion and Involved in the Regulation of Suicidal Erythrocyte Death

JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis

Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma

Novel JAK3 -Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type

Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor

In vivo impact of JAK3 A573V mutation revealed using zebrafish

JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma

In silico screening of a series of 1,6-disubstituted 1 H -pyrazolo[3,4- d ]pyrimidines as potential selective inhibitors of the Janus kinase 3

In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

JAK3: A two-faced player in hematological disorders

Janus kinase 3 deficiency caused by a homozygous synonymous exonic mutation that creates a dominant splice site

Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting

Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity

Suchergebnisse filtern